CRISPR and Cas Genes Market Snapshot
“The CRISPR and Cas Genes Market is estimated to increase at a CAGR 20.35% from $ 2.7 Billion in 2023 to $ 15.4 Billion by 2030.”
Genome editing, or gene editing, allows scientists to alter an organism's DNA by inserting, deletion, or modifying genetic material at specific genomic regions.
CRISPR-Cas9, a well-known example, offers advantages over existing genome editing techniques such as speed, affordability, accuracy, and efficiency. The scientific community is excited about the CRISPR-Cas9 system due to its potential for advancements in genetic engineering.
CRISPR-Cas9 is derived from the naturally occurring genome editing mechanism used by bacteria as an immunological response. Bacteria infected with viruses seize fragments of the virus's DNA and reposition them within their own DNA to form CRISPR arrays.
These arrays enable bacteria to "remember" viruses and create RNA segments that can connect to specific DNA sequences on the viruses. The bacteria then use Cas9 or a related enzyme to split the DNA, rendering the virus inoperable.
Genome editing is being used in research labs to study and treat various diseases, including single-gene conditions like hemophilia, sickle cell disease, and cystic fibrosis.
It has potential applications in managing and avoiding more complicated illnesses like mental illness, heart disease, cancer, and HIV infection. Researchers are still determining the safety and benefits of using this method on humans.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/crispr-and-cas-genes-market-54675
Key Takeaways
- The market is segmented into various product categories such as kits & enzymes, vector-based Cas, DNA-free Cas, libraries, design tools, antibodies, and others.
- The market is segmented into Cell Line Engineering, gRNA Design, Microbial Gene Editing, and DNA Synthesis based on service offerings.
- The market is categorized into various applications such as Biomedical, Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others, and Agricultural.
- The market is categorized into three groups based on end-use: Biotechnology and Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs).
Growth Drivers
- Growing demand for cutting-edge treatments
- Growing interest in gene editing
- increasing cancer incidence
The CRISPR and Cas genes market is expanding rapidly due to increased public and private investment in developing novel treatments. The market is expected to grow in the coming years due to the growing prevalence of cancer and hereditary illnesses. Technological advancements in the CRISPR industry are expected to drive demand in the target market.
Furthermore, increased research and studies on CAS and CRISPR gene technologies conducted by various experts worldwide are driving revenue growth in this industry. In addition, a lot of organizations are currently focusing on launching cutting-edge clinical studies for the CRISPR and Cas genes to treat cancer. For instance, in 2022, American companies funded the groundbreaking in-human clinical study of CRISPR genome editing technology, which was introduced by CRISPR Therapeutics and Vertex.
Restraints
Companies and academic institutions are actively exploring new applications for CRISPR and Cas genes, leading to a rapid growth in the gene-editing patent market. Additionally, the technology's increased use for non-traditional and medical purposes is also driving the market for these genes.
The global CRISPR and Cas gene market is expected to be limited due to ethical and safety concerns surrounding gene editing and genetically engineered foods or organisms, with the primary ethical concern being the modification of the human germline.
CRISPR and Cas Genes Market Segment Analysis
The genome engineering sector is expected to grow due to increased funding and genomics research activities. CRISPR-associated protein 9 (Cas9) is a nuclease used in genome engineering to cleave DNA sequence-specifically at genomic sites upstream of the protospacer adjacent motif (PAM).
CRISPR technology allows for the introduction of specific mutations into mammalian cells, leading to loss-of-function abnormalities. It has also been used to examine virus-host interactions, identifying host traits that prevent viral infections through genome-wide CRISPR screening.
The market for CRISPR-Cas-based techniques is divided into knockdown/activation, functional genomes, disease models, and genome engineering. Genome engineering is expected to be the most popular use, accounting for over half of the overall market share. The potential uses of genome engineering are expected to expand due to programmable transcriptomic, epigenetic, and genetic engineering.
The widespread use of CRISPR-Cas systems in research initiatives and immunology-focused applications, such as targeting the gene for programmed death-1 and the C-C chemokine receptor type 5, will also impact the market.
Competitive Landscape of the CRISPR and Cas Genes Market Analysis
New Developments in CRISPR and Cas Genes Market
In February 2023, Ensoma, a genomic medicines company acquired Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. This strategy helped the company to expand its service portfolio and customer base.
December 2022: A researcher from the University of California sponsored a clinical trial under the title "Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease" to evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR_SCD001 Drug Product).
Editas Medicine stated that it has reclaimed complete ownership of a set of investigational CRISPR-based gene editing medicines for eye illnesses from AbbVie Inc.
Intellia Therapeutics, Inc. released preclinical data for NTLA-5001, the company's wholly-owned Wilms' Tumor 1-directed TCR-T cell therapy candidate for the treatment of acute myeloid leukemia.
Regional Analysis of Global CRISPR and Cas Genes Industry
The US is predicted to lead the global market for CRISPR and Cas genes due to its advanced healthcare system, high prevalence of chronic illnesses, and favorable healthcare legislation, and its growth is driven by biopharmaceutical R&D and pharmaceutical company involvement in genome editing drug development.
The German industry is expected to experience growth due to the demand for innovative treatments, the presence of large pharmaceutical and gene therapy businesses, and increased research approvals, along with reassurances in healthcare regulations and increased funding for biotechnology and genomics programs.
Japan's market for genetically modified treatments is expected to grow rapidly due to clinical trials and increased genome-editing research projects. The demand for genetically modified treatments for long-term illnesses like cancer is expected to boost growth prospects. The market expansion is driven by expanding R&D by firms and research organizations, the growing popularity of CRISPR technology, and increased government spending on research and development for new treatments.
Segments Covered in the CRISPR and Cas Genes Market Report
Market by Product & Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others
By Application
- Agricultural
- Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others
End-use Outlook
- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
Market by Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Frequently Asked Questions
What are some applications of CRISPR and Cas Genes?
The market is categorized into various applications such as Biomedical, Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others, and Agricultural.
What is the expected growth rate of the CRISPR and Cas Genes market over the next 7 years?
The CRISPR and Cas Genes Market is estimated to increase at a CAGR 20.35% from $ 2.7 Billion in 2023 to $ 15.4 Billion by 2030.
Who are the major players in the CRISPR and Cas Genes market and what is their market share?
AstraZeneca plc, Addgene , Cellectis, CRISPR Therapeutics, Caribou Biosciences, Inc., Synthego, Editas Medicine, Inc., GenScript, Lonza Group AG, Beam Therapeutics, are prominent players operating and dominating in the market.
Who are the top 3 CRISPR and Cas Genes Market Key Vendors?
AstraZeneca plc, Addgene , Cellectis, are key players in the CRISPR and Cas Genes market.
Which geographical areas dominate the worldwide market for CRISPR and Cas Genes?
North America region are emerging as the top regional markets for CRISPR and Cas Genes solutions.
1.SUMMARY
1.1. CRISPR and Cas Genes Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of CRISPR and Cas Genes
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of CRISPR and Cas Genes
3.7 Challenges associated with CRISPR and Cas Genes
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 CRISPR and Cas Genes: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. CRISPR and Cas Genes: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. CRISPR and Cas Genes: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. CRISPR and Cas Genes: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved CRISPR and Cas Genes
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- AstraZeneca plc
- Addgene
- Cellectis
- CRISPR Therapeutics
- Caribou Biosciences, Inc.
- Synthego
- Editas Medicine, Inc.
- GenScript
- Lonza Group AG
- Beam Therapeutics
